200 related articles for article (PubMed ID: 31206608)
21. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment.
Marchesi F; Cenfra N; Altomare L; Dessanti ML; Mecarocci S; Cerchiara E; Rago A; D'Andrea M; Tomarchio V; Olimpieri OM; Tirindelli MC; Mengarelli A; Petti MC; Avvisati G; Cimino G
J Geriatr Oncol; 2013 Jul; 4(3):242-8. PubMed ID: 24070462
[TBL] [Abstract][Full Text] [Related]
23. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
24. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M; Murawski N; Zeynalova S; Ziepert M; Loeffler M; Hänel M; Dierlamm J; Keller U; Dreyling M; Truemper L; Frickhofen N; Hünerlitürkoglu AN; Schmitz N; Pöschel V; Rixecker T; Berdel C; Rübe C; Held G; Zwick C
Br J Haematol; 2017 Nov; 179(3):410-420. PubMed ID: 28990173
[TBL] [Abstract][Full Text] [Related]
25. Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.
Sakurai M; Karigane D; Kasahara H; Tanigawa T; Ishida A; Murakami H; Kikuchi M; Kohashi S
Ann Hematol; 2019 Mar; 98(3):669-678. PubMed ID: 30443764
[TBL] [Abstract][Full Text] [Related]
26. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.
Chiappella A; Castellino A; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Apr; 10(4):289-297. PubMed ID: 28290728
[TBL] [Abstract][Full Text] [Related]
27. [The prognostic effects of two comprehensive geriatric assessment methods in elderly patients with acute myeloid leukemia].
Zhang S; Feng R; Li JT; Wang T; Zhang CL; Bai JF; Li Y; Shao RY; Liu H
Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):880-885. PubMed ID: 34551476
[No Abstract] [Full Text] [Related]
28. Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches.
Allen P
Curr Oncol Rep; 2020 Aug; 22(11):114. PubMed ID: 32827063
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
Gobba S; Moccia AA; Gulden-Sala W; Conconi A; Diem S; Cascione L; Iacoboni G; Margiotta-Casaluci G; Aprile von Hohenstaufen K; Stathis A; Hitz F; Pinotti G; Gaidano G; Zucca E
Hematol Oncol; 2018 Feb; 36(1):84-92. PubMed ID: 28621491
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
[TBL] [Abstract][Full Text] [Related]
31. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).
Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
BMC Cancer; 2017 Jun; 17(1):448. PubMed ID: 28659138
[TBL] [Abstract][Full Text] [Related]
32. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
33. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
34. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M; Huntington SF; Olszewski AJ
Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
[TBL] [Abstract][Full Text] [Related]
35. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Stephens DM; Li H; LeBlanc ML; Puvvada SD; Persky D; Friedberg JW; Smith SM
J Clin Oncol; 2016 Sep; 34(25):2997-3004. PubMed ID: 27382104
[TBL] [Abstract][Full Text] [Related]
36. Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era.
Ha H; Keam B; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):304-11. PubMed ID: 25865654
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
39. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
[No Abstract] [Full Text] [Related]
40. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
